Oncolytics wins FDA Fast Track for pelareorep in second-line anal cancer

Oncolytics Biotech announced on July 20, 2026 that the FDA granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for treating patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who have progressed on or were intolerant to one or more prior lines of systemic therapy.¹

Fast Track status is meant to speed up development and review of treatments for serious conditions with unmet needs, and it comes with certain benefits. These include more frequent FDA interactions during development, the option for a rolling review of a future Biologics License Application, and potential eligibility for Priority Review.¹

The company said the decision follows positive feedback from an April 2026 FDA meeting on a possible registrational strategy for the program, and that based on that feedback it believes a clear regulatory pathway exists for a pivotal study in this indication.¹

Supporting data cited comes from the company's GOBLET study. The designation draws on efficacy results from the GOBLET study testing pelareorep with a checkpoint inhibitor in advanced anal cancer patients who had progressed after prior therapy, showing an objective response rate of about 30%, more than double historical rates, a median duration of response near 15.5 months versus 9.5 months, and a 12-month overall survival rate of 82% compared to 45.7%.¹

This marks pelareorep's third Fast Track designation in gastrointestinal cancers. The prior two came for KRAS-mutated metastatic colorectal cancer in February 2026 and for pancreatic cancer in late 2022.¹ CEO Jared Kelly said the milestone reflects progress made over the past year and represents another important regulatory milestone for the company.¹